13. Polivy


Active ingredient: polatuzumab vedotin
Disease: diffuse large B-cell lymphoma
Peak sales estimate: $1 billion
Approved: June 10, 2019
Company: Roche

The scoop: Roche’s Polivy is a first-in-class drug and used in a cocktail treatment regimen to treat diffuse large B-cell lymphoma (DLBCL) patients who've failed on at least two prior treatments. In a note to clients, Jefferies analysts wrote that the drug could pull in $1 billion at peak if it garners 50% of the market in r/r DLBCL in the U.S. and Europe, and 25% of the first-line market. Former Roche Pharmaceuticals CEO Daniel O’Day—who now heads up Gilead Sciences—previously said he sees the drug “shifting the standard of care” in the disease, similar to the way Roche's Gazyva has in chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. — Ben Adams

13. Polivy

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.